Therapeutic Equivalence Codes: How the FDA Rates Generic Drug Substitutability

When you pick up a prescription at the pharmacy, you might not think about whether the pill in your hand is exactly the same as the brand-name version your doctor ordered. But behind every generic drug substitution is a rigorous, science-based system designed to make sure it’s safe and effective. That system is the FDA’s therapeutic equivalence (TE) codes - a simple but powerful tool that tells pharmacists whether a generic drug can be swapped in without changing how well it works or how safe it is.

What TE Codes Actually Mean

Therapeutic equivalence isn’t just about having the same active ingredient. Two drugs can have identical ingredients but still behave differently in your body. That’s why the FDA doesn’t just look at the label - it checks how the drug is absorbed, how it moves through your system, and whether it delivers the same clinical result. TE codes are the FDA’s way of saying, "Yes, this generic can be swapped" or "Not yet, we need more data."

The system is published in the Orange Book - officially called Approved Drug Products with Therapeutic Equivalence Evaluations. It’s been around since 1980, but it’s still the backbone of how generics are approved and substituted today. Every time a new generic hits the market, the FDA reviews it and assigns a code based on two big factors: pharmaceutical equivalence and bioequivalence.

Pharmaceutical equivalence means the generic has the same active ingredient, strength, dosage form (like tablet or injection), and route of administration (oral, topical, etc.) as the brand-name drug. But that’s just the start. Bioequivalence is the real test: does the generic get into your bloodstream at the same rate and amount as the original? If yes, it gets an "A" code. If not - or if there’s uncertainty - it gets a "B" code.

The Letter Codes: A and B Explained

The TE code system uses letters to make things quick and clear for pharmacists. The first letter tells you the big picture:

• A = Therapeutically equivalent. This is the gold standard. You can swap it with confidence.
• B = Not yet determined. This doesn’t mean it’s unsafe - just that the FDA needs more evidence before it can say it’s interchangeable.

But there’s more detail hidden in the letters after the first one. For example:

• AB = Bioequivalent to the reference drug. Most common for simple oral pills.
• AB1, AB2, AB3, AB4 = Used when there are multiple brand-name drugs (reference listed drugs) for the same generic. Each number points to which brand it matches.
• BC = Extended-release product with bioequivalence issues. These are tricky - the drug is designed to release slowly, and small differences can matter.
• BT = Topical product (like creams or gels) with potential bioequivalence problems.
• BN = Aerosol or nebulizer products. Hard to test because delivery depends on how you use it.
• BX = Not enough data to rate. These aren’t approved for substitution yet.

Over 90% of all generic drugs in the U.S. carry an "A" rating. That’s why pharmacists can substitute them automatically in 49 states without asking the doctor first. But the "B" codes? They’re where things get messy.

Why "B" Codes Cause Confusion

Here’s the problem: a "B" doesn’t mean the drug is bad. It means the FDA hasn’t confirmed it’s interchangeable. Some "B"-rated drugs are clinically identical to the brand. But because they’re complex - like inhalers, injectables, or skin creams - the standard blood tests used for pills don’t always capture how well they work.

For example, a topical cream might have the same active ingredient, but if the base (the lotion part) is different, it might not absorb the same way. The FDA doesn’t yet have a reliable way to test that, so it gives it a "BT" code. But doctors and patients may have used it for years with no issues.

A 2022 survey by the American Medical Association found that 42% of physicians didn’t fully understand how to interpret "B" codes. Some refused to let pharmacists substitute them - even when the drug was safe. Others didn’t realize the code meant "more data needed," not "dangerous."

And pharmacists? They’re caught in the middle. A 2023 study showed they spend an average of 2.7 minutes per prescription checking TE codes. That’s time they could spend counseling patients. But if they substitute a "B"-rated drug without checking the doctor’s intent, they risk liability.

How Pharmacists Use TE Codes Every Day

For most prescriptions, the process is simple:

1. The doctor writes a prescription for a brand-name drug.
2. The pharmacy checks the Orange Book for the TE code.
3. If it’s "A," they dispense the generic - no questions asked.
4. If it’s "B," they may need to call the doctor to confirm whether substitution is allowed.

State laws vary. In 38 states, pharmacists must notify the prescribing doctor if they switch a "B"-rated drug. In others, substitution is blocked entirely unless the doctor checks a box on the prescription saying "dispense as written."

Pharmacists rely on the Orange Book website daily. In Q2 2023 alone, it had 1.7 million unique visitors - mostly pharmacists, doctors, and pharmacy students. The FDA updates it monthly, adding new generics and changing codes as new studies come in.

Training for pharmacy students includes 4 to 6 hours of focused TE code instruction. That’s because getting it wrong can have consequences. A mistake in substitution might mean a patient gets a drug that doesn’t work as well - or worse, one that causes side effects.

The Bigger Picture: Savings and Complexity

Generic drugs make up 90% of all prescriptions filled in the U.S., but they cost only 23% of what brand-name drugs do. That’s where the TE code system shines: it lets pharmacists swap in cheaper versions without compromising safety. In 2023 alone, generic substitution saved the U.S. healthcare system an estimated $370 billion.

But as drugs get more complex - think biologics, inhalers, and injectables - the old system struggles. Between 2018 and 2022, applications for "B"-rated complex generics jumped 22%. The FDA admits its current methods aren’t always enough to prove equivalence for these products.

That’s why the agency released a draft guidance in 2022 proposing new ways to evaluate complex generics. They’re exploring things like real-world data, in vitro testing, and even patient outcomes - not just blood levels. Their goal? To reduce "B"-rated products for complex drugs by 30% by 2027.

How This Compares to Other Countries

The U.S. system is unique. In Europe, the EMA doesn’t use a code system. Instead, each generic gets a detailed scientific review. That’s thorough - but it doesn’t give pharmacists a quick "yes" or "no" for substitution. In many European countries, substitution isn’t automatic. The doctor has to specifically write "dispense as prescribed."

The FDA’s TE code system is more practical for high-volume pharmacies. It’s fast, clear, and built into state laws. But it’s not perfect. It works best for simple pills. For everything else - inhalers, patches, eye drops - it’s still playing catch-up.

What’s Next for TE Codes?

The future of therapeutic equivalence is about adapting to modern medicine. The FDA is working on Product-Specific Guidelines (PSGs) - detailed roadmaps for how to test bioequivalence for each drug. There are now over 1,850 of them. These help companies get "A" ratings faster.

More importantly, the agency is moving toward using real-world evidence. If thousands of patients have used a generic cream for years with no issues, maybe that’s enough proof - even without a perfect blood test.

One thing won’t change: the goal. The TE code system exists to make safe, affordable drugs accessible. It’s not about cutting corners. It’s about using science to make sure patients get the right treatment, at the right price.